银诺医药-B涨超4% 核心产品依苏帕格鲁肽α在澳门正式进入商业化销售阶段

Core Viewpoint - Silver诺医药-B (02591) has seen a stock price increase of over 4%, currently trading at 46.3 HKD with a transaction volume of 12.5852 million HKD, following the announcement of its core product's market expansion [1] Group 1: Product Development and Approval - The company is actively advancing the global expansion of its core product, Isuparaglutide α [1] - The product received BLA (Biologics License Application) approval for the treatment of Type 2 Diabetes (T2D) in Macau by June 2025 [1] - The first prescription for the core product for T2D treatment was issued at the Huabao Medical Center in Macau on September 12, 2025, marking the official commercialization phase in Macau [1]